Have to say that I disagree with their probability for success of LANI and the potential market size, but anyhow good to see someone out there is watching.
http://www.biota.com.au/uploaded/154/1021394_10abnamromorgansbta10808-.pdf
Target price $1.29 (72% from these levels and using what looks like conservative valuation measures).
Trouble is, there is little news for a while... perhaps HRV testing but I fear that the market will write off Biota for a while due to bad sentiment from the GSK settlement. A deal for LANI should reverse that but now the Phase II worked well in a large patient sample I personally wouldn't mind if Biota waited till phase III completed before partnering the compound. Then again, GSK are probably sniffing some sort of partnership deal.
Does anyone have a reference where Biota management suggested even GSK could be a potential partner for LANI. I remember seeing or hearing it somewhere but for the life of me I just can't remember. Perhaps a news interview?
- Forums
- ASX - By Stock
- BTA
- upgrade from abn amro
upgrade from abn amro
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online